MedTrace Logo

PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery

NCT00002930 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2013-01-18

No results posted yet for this study

Summary

RATIONALE: Imaging procedures, such as fludeoxyglucose F 18 positron emission tomography (PET) scans, may improve the ability to detect lung and esophageal cancer or their recurrence.

PURPOSE: Phase II/III trial to study the effectiveness of fludeoxyglucose F 18 PET scans in measuring response to induction chemotherapy in patients with esophageal and lung cancer that may be removed by surgery.

Conditions

Interventions

PROCEDURE

positron emission tomography

RADIATION

fludeoxyglucose F 18

Sponsors & Collaborators

Principal Investigators

  • Robert J. Downey, MD · Memorial Sloan Kettering Cancer Center

Study Design

Purpose
DIAGNOSTIC

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-12-31
Primary Completion
2002-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002930 on ClinicalTrials.gov